ProCE Banner Activity


Advances in Precision Medicine for Gynecologic Cancers: Clinical Application for Nursing Practice

In this on-demand webcast from a live webinar, oncology nursing experts discuss the latest evidence on approved and investigational therapies for the treatment of cervical, endometrial, and ovarian cancers.

Nurses: 1.00 Nursing contact hour

Released: September 02, 2022

Expiration: September 01, 2023

No longer available for credit.



Courtney Arn

Courtney Arn, CNP

CNP, Gynecologic Oncology
Women’s Health Nurse Practitioner, Gynecologic Oncology
The Ohio State University
Columbus, Ohio

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by an educational grant from


Target Audience

This program is intended for oncology nurses and other HCPs who care for patients with gynecologic cancers.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Discuss with patients the available data surrounding the rationale for targeting predictive biomarkers in gynecologic malignancies
  • Counsel patients on the administration and potential toxicities of immune checkpoint inhibitors and PARP inhibitors as single-agent or combination therapies for the treatment of cervical, endometrial, and ovarian cancer
  • Describe available maintenance therapies for patients with ovarian cancer with or without BRCA mutations or other homologous recombination repair deficiencies in the frontline and relapsed settings
  • Recognize and manage irAEs in patients receiving immune checkpoint inhibitor therapy
  • Develop a proactive management plan to support adherence in patients receiving oral PARP inhibitor therapy


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

Courtney Arn, CNP

CNP, Gynecologic Oncology
Women’s Health Nurse Practitioner, Gynecologic Oncology
The Ohio State University
Columbus, Ohio

Courtney R. Arn, APRN-CNP: consultant/advisor/speaker: AstraZeneca, Eisai, Genmab, Merck, Seagen.

Staff Disclosure


Krista Marcello,

Associate Managing Editor

Krista Marcello has no relevant financial relationships to disclose.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant financial relationships to disclose.

Shara Pantry, PhD

Associate Scientific Director

Shara Pantry, PhD, has no relevant financial relationships to disclose.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant financial relationships to disclose.

Kristen Rosenthal, PhD

Clinical Editor

Kristen Rosenthal, PhD, has no relevant financial relationships to disclose.

Instructions for Credit


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from September 02, 2022, through September 01, 2023:

1. Register online at
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


The goal of this activity is to improve oncology nurses’ ability to educate and optimally care for patients with gynecologic malignancies.